Jubilee Brown on Genetic Counseling for Patients With Breast and Ovarian Cancer

Eight-year follow-up showed that Tafinlar plus Mekinist continued to improve outcomes for patients with stage 3 melanoma.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

An Adcetris-based treatment regimen improved progression-free survival and was more tolerable for patients with classical Hodgkin lymphoma.

One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.

From NBA Hall of Famer Bill Walton dying from cancer to an ancient skull showing evidence of early cancer treatments, here’s what’s happening in the oncology space this week.

Scemblix outperformed standard tyrosine kinase inhibitor treatment in patients with Philadelphia chromosome-positive chronic myeloid leukemia.